Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers

Area of Science:

• Oncology
• Pharmacology
• Cancer Therapeutics

Background:

• The US Food and Drug Administration (FDA) approved selective RET inhibitors selpercatinib and pralsetinib.
• These drugs represent a paradigm shift in treating RET-altered lung and thyroid cancers.
• Recent approvals include tissue-agnostic use for selpercatinib and pan-cancer activity for pralsetinib.

Purpose of the Study:

• To review potential toxicities associated with selective RET inhibitors.
• To discuss strategies for optimal management of these toxicities.
• To maximize clinical benefit for patients treated with these novel agents.

Main Methods:

• Literature review of clinical trials and post-marketing data.
• Analysis of safety and efficacy profiles of selpercatinib and pralsetinib.
• Synthesis of current evidence on managing adverse events.

Main Results:

• Selective RET inhibitors demonstrate higher response rates and better tolerability compared to multi-kinase inhibitors.
• Potential toxicities include [specific toxicities to be detailed in the full review].
• Effective management strategies can mitigate most adverse events.

Conclusions:

• Selpercatinib and pralsetinib are effective in treating RET-altered cancers.
• Understanding and managing potential side effects is crucial for maximizing therapeutic success.
• Proactive management strategies are essential for optimal patient outcomes.